WFA
ALXO icon

Wipfli Financial Advisors’s ALX Oncology ALXO Stock Holding History

Wipfli Financial Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3K Buy
+359
New +$4.18K ﹤0.01% 2184

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wipfli Financial Advisors's ALXO Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in ALX Oncology (ALXO) in Q3 2022: 359 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #2184 among its holdings.

99 funds tracked by Wall St. Rank hold ALXO as of Q3 2022.

  • Wipfli Financial Advisors held 359 shares of ALX Oncology worth $3K as of Q3 2022.
  • ALX Oncology was a new Wipfli Financial Advisors position in Q3 2022.
  • ALX Oncology made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2184 holding.
  • 99 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.